The Prescription Pad Weighs More Than the Clock: Ruti Aga's Six Years and Anti-Doping's Own Audit Gap

The clinic's reply was one line: that prescription pad is not ours. The document Ruti Aga produced to justify her knee treatment had been written by a family member with no medical registration, using a pad supposedly salvaged from a former workplace the clinic flatly denies ever issuing. Between those two sentences, a marathon career folded.

Six years, counted from 10 September, the date her provisional suspension took effect. She is 32. The arithmetic is simple: she returns at 38.

The number shouting loudest in this case is not a finishing time. It is four plus two. The substance carried two years; the paper carried four. Four of the six years came from documentation, not from blood.

Four fields on my worksheet are still blank: the name of the March half marathon, the winning time, the sample type, and the year the decision was announced. I will not build a timing analysis on that many zeros. What can be audited is the process.

In 2026, at the National Athletics Championships in Dhaka, I audited 47 years of federation results and tagged 212 men's 100m performances hand-timed or electronic. Where the clock said 0.31, the whole calculation changed its mind. That gave me a habit: careers end twice — once in the body, once in the paperwork. The paperwork usually goes first.

Context matters. On the WADA Prohibited List, methylprednisolone belongs to the glucocorticoid class, prohibited in-competition. Out of competition it is usable, and with a valid Therapeutic Use Exemption it is usable inside competition too. The question is not whether she used it. The question is why it was detectable on race day, and whether she could document a lawful reason.

The second charge is tampering. Submitting a fabricated prescription is not only doping; it is obstructing the investigation. The two charges run on separate rails and pull separate penalties — and there the real story sits.

Fix the competitive tier first. A 2026 Tokyo Marathon win plus three World Marathon Major runner-up finishes places her in the global top fifteen to twenty-five band, not the top three. She was the kind of marathoner whose income came from showing up, not from record-breaking: appearance fees. Global sponsorship never reached her, because sponsorship looks for record-tier faces. Without that economic structure, the six-year blow cannot be located.

In March she won a half marathon in China — a label race at the edge of the international circuit, where big names are invited for fees and where testing volume is set by the local NADO and targeted surveillance rather than the race's commercial profile. That is the classic exposure zone for a mid-tier elite: high fee, low surveillance.

The substance itself raises little doubt. Knee pain and patellofemoral loading are routine in professional marathon careers, and glucocorticoid injections are exactly what such complaints receive. I trust the spreadsheet, but I still audit the story. The story is credible. Credibility is not legality. Detection on race day means either the clearance did not exist or the paper did not exist.

The second crack is deeper. The prescription was written by a family member with no medical licence, who claimed to have used an old pad from a former workplace that denies ever having one. That denial, not a lab report, is the heaviest evidence against her.

Here the structural truth surfaces. Much of the East African marathon economy runs on agent-centred, informal entourages without a licensed team physician, a TUE-signing doctor, or a medical compliance officer. TUE literacy is an infrastructure advantage, not a moral superiority. The athlete with that infrastructure returns in zero years for the same injection; the athlete without it gets six. Ban length becomes a proxy for access, not for severity.

Look at the arithmetic again: two years for presence and use, four for tampering, six total. No prior sanction appears in the record, so no repeat-offender escalation applied, and lifetime was never on the table. The panel treated the fabrication as an additional offence, not as evidence of concealment. That distinction matters: they did not conclude she ran a systematic programme and hid it; they concluded one bad decision produced another.

The result annulled is not Tokyo 2026. It is the March half marathon — title, prize money, ranking points. The metric that now carries the most weight is not a time; it is an annulment.

Financially it is brutal. An appearance-fee athlete earns almost entirely by starting races. Six years away removes her from competition and from the agent network that generates major invitations. A return at 38 is not theoretically impossible — the marathon peak sits roughly 27 to 33 with outliers past 35 — but six years outside testing and outside elite training groups does not produce major-level comebacks.

Now the part no official explanation will state. Anti-doping's heaviest artillery points at its own audit trail, not at blood. The system's legitimacy rests on trust, and broken trust cannot be survived. Penalising tampering harshly is coherent. The side effect goes unmeasured: an athlete without medical infrastructure, after a misunderstanding, reaches for paper — and if the paper is proven false, the penalty doubles. Structural weakness converts into moral offence, and the sentencing table never records the difference.

My own market offers the comparison. Across 47 years of Bangladeshi national records I have not found a single doping case. That is not cleanliness; it is a denominator problem. Our athletes never reach a testable tier, so they are never caught. Where eight divisional headquarters lack a synthetic track, who funds sample collection? A zero positive rate is an empty row, not an achievement.

My 2026 audit taught me that measurement error is correctable — but only if someone agrees to audit. In Aga's case the audit happened, and it ran against her. The best models are janitors: they clean context before they predict. Here the context was cleaned in reverse: the denial of a prescription pad became the foundation of the entire decision.

What to watch: whether the case goes to CAS, where the four-year tampering component is most exposed; how the Chinese organiser handles the annulled result and prize clawback; and whether sports bodies begin distinguishing doping from documentation failure in penalty design.

One question remains. If the same injection, the same knee, the same explanation produces zero years for a European marathoner with a licensed team doctor and six years for an Ethiopian marathoner with a prescription written by a relative — what exactly are we punishing? The drug, or the missing infrastructure?